Patent search ap:("Genentech Page Inc.") AND inv:"Johann Karl"

1.

发明申请
METHOD TO IDENTIFY A PATIENT WITH AN INCREASED LIKELIHOOD OF RESPONDING TO AN ANTI-CANCER THERAPY 审中-公开

公开(公告)号：US20140017232A1

公开(公告)日：2014-01-16

申请号：US13802394

申请日：2013-03-13

Applicant: HOFFMANN-LA ROCHE INC. , GENENTECH. INC.

Inventor： Herbert Andres , Sanne Lysbet De Haas , Rebecca Elliott , Johann Karl , Yu-Ju Gloria Meng , Gregory D. Plowman , Stefan Scherer , Norbert Wild

IPC: G01N33/74 , A61K45/06 , A61K39/395

CPC classification number: C07K16/22 , A61K31/337 , A61K31/513 , A61K31/517 , A61K31/70 , A61K31/7068 , A61K33/00 , A61K33/24 , A61K38/43 , A61K39/3955 , A61K39/39558 , A61K45/06 , G01N33/57434 , G01N33/57492 , G01N33/6893 , G01N33/74 , G01N2333/475 , G01N2800/52

Abstract: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.

2.

发明申请
METHOD TO IDENTIFY A PATIENT WITH AN INCREASED LIKELIHOOD OF RESPONDING TO AN ANTI-CANCER THERAPY 审中-公开
Title translation: 识别患有抗癌药治疗的增加症状的患者的方法

公开(公告)号：US20140193397A1

公开(公告)日：2014-07-10

申请号：US13802333

申请日：2013-03-13

Applicant: Hoffmann-La Roche Inc. , Genentech. Inc.

Inventor： Herbert Andres , Sanne Lysbet De Haas , Rebecca Elliott , Johann Karl , Yu-Ju Gloria Meng , Gregory D. Plowman , Stefan Scherer , Norbert Wild

IPC: G01N33/74 , A61K31/337 , A61K31/517 , A61K33/24 , A61K31/7068 , C07K16/22 , A61K39/395 , A61K31/513

CPC classification number: C07K16/22 , A61K31/337 , A61K31/513 , A61K31/517 , A61K31/70 , A61K31/7068 , A61K33/00 , A61K33/24 , A61K38/43 , A61K39/3955 , A61K39/39558 , A61K45/06 , G01N33/57434 , G01N33/57492 , G01N33/6893 , G01N33/74 , G01N2333/475 , G01N2800/52

Abstract: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.

Abstract translation: 本发明提供了用于鉴定可能受益于包含VEGF拮抗剂的抗癌疗法治疗的患者的方法。本发明还提供了用于监测患者对抗癌疗法的反应的方法。本发明还提供用于该方法的试剂盒和制品。

3.

发明申请
METHOD TO IDENTIFY A PATEINT WITH AN INCREASED LIKELIHOOD OF RESPONDING TO AN ANTI-CANCER THERAPY 审中-公开

公开(公告)号：US20140056875A1

公开(公告)日：2014-02-27

申请号：US13802303

申请日：2013-03-13

Applicant: Genentech. Inc. , Hoffmann-La Roche Inc.

Inventor： Herbert Andres , Sanne Lysbet De Haas , Rebecca Elliott , Johann Karl , Yu-Ju Gloria Meng , Gregory D. Plowman , Stefan Scherer , Norbert Wild

IPC: G01N33/574 , A61K45/06 , A61K39/395

CPC classification number: C07K16/22 , A61K31/337 , A61K31/513 , A61K31/517 , A61K31/70 , A61K31/7068 , A61K33/00 , A61K33/24 , A61K38/43 , A61K39/3955 , A61K39/39558 , A61K45/06 , G01N33/57434 , G01N33/57492 , G01N33/6893 , G01N33/74 , G01N2333/475 , G01N2800/52

Abstract: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.

4.

发明申请
METHOD TO IDENTIFY A PATIENT WITH AN INCREASED LIKELIHOOD OF RESPONDING TO AN ANTI-CANCER THERAPY 审中-公开

公开(公告)号：US20140023639A1

公开(公告)日：2014-01-23

申请号：US13802379

申请日：2013-03-13

Applicant: Genentech. Inc. , Hoffmann-La Roche Inc.

Inventor： Herbert Andres , Sanne Lysbet De Haas , Rebecca Elliott , Johann Karl , Yu-Ju Gloria Meng , Gregory D. Plowman , Stefan Scherer , Norbert Wild

IPC: G01N33/74 , A61K39/395

CPC classification number: C07K16/22 , A61K31/337 , A61K31/513 , A61K31/517 , A61K31/70 , A61K31/7068 , A61K33/00 , A61K33/24 , A61K38/43 , A61K39/3955 , A61K39/39558 , A61K45/06 , G01N33/57434 , G01N33/57492 , G01N33/6893 , G01N33/74 , G01N2333/475 , G01N2800/52

Abstract: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.

5.

发明申请
BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER 审中-公开
Title translation: 用于BEVACIZUMAB联合治疗乳腺癌的血浆等离子体生物标志物

公开(公告)号：US20140341893A1

公开(公告)日：2014-11-20

申请号：US14289524

申请日：2014-05-28

Applicant: Genentech, Inc.

Inventor： Herbert Andres , Sanne Lysbet de Haas , Rebecca Elliott , Johann Karl , Yu-Ju Gloria Meng , Gregory D. Plowman , Stefan Scherer , Norbert Wild

IPC: A61K39/395 , C07K16/22 , G01N33/574 , A61K31/337

CPC classification number: A61K39/39558 , A61K31/337 , C07K16/22 , G01N33/57415 , G01N2333/475

Abstract: The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer, by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of VEGFA and/or VEGFR2 relative to control levels of patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer. The present invention also provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, by determining the expression level, in particular the blood plasma expression level, of VEGFA and/or VEGFR2 relative to control levels in patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer.

Abstract translation: 本发明提供了通过将化疗方案添加到化疗方案中来改善患有HER2阳性乳腺癌，特别是局部复发或转移性HER2阳性乳腺癌的患者的化疗方案的治疗效果的方法，相对于诊断为HER2阳性乳腺癌，特别是局部复发或转移性HER2阳性乳腺癌的患者的对照水平，VEGFA和/或VEGFR2的水平，特别是血浆表达水平。本发明还提供了通过确定VEGFA和/或VEGFR2相对的表达水平，特别是血浆表达水平来评估患者与贝伐珠单抗（Avastin？）联合化疗方案的敏感性或反应性的方法以控制诊断为HER2阳性乳腺癌，特别是局部复发或转移性HER2阳性乳腺癌患者的水平。

6.

发明申请
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy 审中-公开

公开(公告)号：US20130344059A1

公开(公告)日：2013-12-26

申请号：US13744140

申请日：2013-01-17

Applicant: Genentech. Inc. , Hoffmann-La Roche Inc.

Inventor： Herbert Andres , Sanne Lysbet De Haas , Rebecca Elliott , Johann Karl , Yu-Ju Gloria Meng , Gregory D. Plowman , Stefan Scherer , Norbert Wild

IPC: G01N33/68 , A61K45/06 , A61K39/395

CPC classification number: C07K16/22 , A61K31/337 , A61K31/513 , A61K31/517 , A61K31/70 , A61K31/7068 , A61K33/00 , A61K33/24 , A61K38/43 , A61K39/3955 , A61K39/39558 , A61K45/06 , G01N33/57434 , G01N33/57492 , G01N33/6893 , G01N33/74 , G01N2333/475 , G01N2800/52

Abstract: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.

7.

发明申请
METHODS OF IDENTIFYING AN INDIVIDUAL AS HAVING OR BEING AT RISK OF DEVELOPING AN AMYLOID-POSITIVE DEMENTIA BASED ON MARKER MOLECULES AND RELATED USES 有权

公开(公告)号：US20210132085A1

公开(公告)日：2021-05-06

申请号：US17150504

申请日：2021-01-15

Applicant: GENENTECH, INC. , Roche Diagnostics Operations, Inc.

Inventor： Tobias Bittner , Johann Karl , Valeria Lifke , Verena Steffen , Martina Jocham

IPC: G01N33/68 , G01N33/577

Abstract: The present disclosure relates to identifying an individual as having or being at risk of developing an amyloid-positive dementia based on marker molecules amyloid β40 (Aβ40), amyloid β42 (Aβ42) and total Tau (tTau), the use of the marker molecules for the identification of an individual having or being at risk of developing an amyloid-positive dementia and a method for detecting an individual with an increased value for the combination of the marker molecules.